Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Cellular Therapy Clinical Trials

For questions about cellular therapy clinical trials, please email us or call 202-476-5456.

TitleDescriptionKey Eligibility CriteriaSponsor  Investigator Disease Type 
T Cell Therapy Opposing Novel Coronavirus Infection in Immunocompromised Patients
Open label, phase I dose-escalation study to evaluate the safety of coronavirus–specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT).
  • Participants must have received an HSCT ≥28 days and <4 months before study infusion.
  • Participants must be within 18 years of age to 80 years to be enrolled in Arm A or 12 years of age and <18 years of age to be enrolled in arm B.
Catherine Bollard, M.D.Susan Conway, M.D.COVID
Phase I Research Study Utilizing Allogeneic Multi Tumor-Associated Antigen-Specific T lymphocytes to Advance the Care of Patients with High-Risk Solid Tumors (ATTACK)Phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen–specific T cell (TAA-T) therapy for patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy. 


  • Participants must be diagnosed with high-risk solid tumors with known positivity for two or more targeted Tumor-Associated Antigens (TAA) (Wilms tumor 1 (WT1), Preferentially Expressed Antigen of Melanoma (PRAME), and/or Survivin) and relapsed, refractory, and/or minimal residual disease following conventional therapy.
  • Participants must be age 18 years to 60 years old to enroll in arm A or 6 to 18 years old to enroll in arm B.
Catherine Bollard, M.D.Amy Hont, M.D.High-risk solid tumors
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (ATLANTIC)
Open label, phase I dose-escalation study to evaluate the safety of norovirus –specific T cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. 
  • Participants must meet one of the following criteria,  have a primary immunodeficiency (PID) and have not undergone HSCT, undergo HSCT but do not have available donor-derived NSTs, or
    have donors from whom NSTs cannot be generated due to norovirus seronegativity.
Catherine Bollard, M.D.Michael Keller, M.D.Norovirus
Adoptive Cord Blood Immunotherapy using Expanded Cord Blood T cells for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis (CHEERS)
This is a phase I–II dose-finding trial to determine the optimal dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. 
  • Pediatric and adult patients with malignant or nonmalignant diseases who are candidates for transplant.
  • Patients must have a cord blood (CB) unit (or units) matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens.  
Catherine Bollard, M.D.Allistair Abraham, M.D.CMV, EBV, BKV and Adenovirus infections
Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of Very High Risk Hematopoietic Malignancies (RESOLVE)
Phase I dose-escalation trial designed to evaluate the safety of administering rapidly generated tumor multi-antigen associated specific cytotoxic T lymphocytes, to HSCT recipients  or future HSCT recipients  for the treatment of high-risk or relapsed or refractory hematopoietic malignancies. 
  • Prior or anticipated myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant to treat Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Ambiguous lineage leukemia or lymphoma, Chronic Myelogenous leukemia, MDS
  • Participants must be 6 months to 80 years
Catherine Bollard, M.D. David Jacobsohn, M.D.AML, MDS, ALL
Phase I Research on Multi-antigen T cell Infusion against Neuro-oncologic Disease (ReMIND)
Phase I dose-escalation trial designed to evaluate the safety of administering rapidly generated TAA-T to patients who have either newly diagnosed DIPG after standard radiation therapy, or for patients with recurrent, progressive, or refractory high grade CNS malignancies.
  • Patients must have new diagnosis of DIPG or recurrent, progressive or refractory disease after standard treatment high-grade glioma, medulloblastoma, ependymoma, embryonal tumors, choroid plexus carcinoma, other aggressive CNS malignancies. 
  • Participants must be 6 months to 80 years of age at enrollment.
Catherine Bollard, M.D.Eugene Hwang, M.D.High-risk CNS tumors
Mesenchymal Stromal Cells Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery (MeDCaP)
Prospective, open-label, single-center,  phase 1 trial of  designed to assess safety and feasibility of administering allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivered through cardiopulmonary bypass (CPB) in a  homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
  • Participants must be neonatal and young infantile patients who are ≤ 3 months of age scheduled to undergo reparative two-ventricle repair for congenital heart defects.
Catherine Bollard, M.D.Richard Jonas, M.D.Congenital heart disease 
A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia (PLAT-05)
This Phase 1 open-label, non-randomized study to assess the safety, feasibility and efficacy of dual targeting (against CD19 and CD22 antigen) autologous CAR-T cells in pediatric and young adult patients (<31 years old) with relapsed or refractory CD19+ CD22+ leukemia with and without prior history of allogeneic stem cell transplant.
  • Relapsed.refractory B cell Acute Lymphoblastic Leukemia(B-ALL)  or ≥0.01% disease following allogeneic transplant CD19+22+   
  • Participants age ≥18 and <31 years.
Seattle Children’s Hospital and Research InstituteAnant Vatsayan, M.D.Relapsed or refractory B-cell Acute Lymphoblastic Leukemia